Pancragen
Pancreatic bioregulator peptide
Pancreatic tissue bioregulator.
Half-life
~ hours
Mol. weight
~ 518.5 g/mol
Sequence
Lys-Glu-Asp-Trp (KEDW)
Discussions
0 threads
Overview
A short bioregulator peptide studied for regulating gene expression in pancreatic tissue, with proposed support for pancreatic function including the islet cells that produce insulin. It applies the Khavinson bioregulator framework to the pancreas — an organ central to both endocrine (glucose) and exocrine (digestion) function.
Mechanism of action
Pancragen is a bioregulator peptide studied for regulating gene expression in pancreatic tissue. The pancreas serves dual roles — endocrine (insulin-secreting islet cells) and exocrine (digestive enzymes) — and is central to metabolic regulation. Pancragen applies the Khavinson ultra-short-peptide framework to that target, conceptually aiming to support pancreatic cell function. As with all bioregulators, the evidence base is concentrated in one research tradition.
Researched benefits
- Studied for pancreatic support
- Targets the organ central to glucose regulation
- Short bioregulator format
Considerations
- Pancreatic/metabolic disease requires medical care
- Evidence concentrated in one tradition
- Human data limited
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating Pancragen in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on Pancragen:
View Pancragen index on PubMed (NCBI)